LDL-Apheresis Atherosclerosis Regression Study (LAARS): Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis

Circulation

Volumn 93, Issue 10, 1996, Pages 1826-1835

  Kroon, Abraham A ^a   Aengevaeren, Wim R M ^a   Van Der Werf, Tjeerd ^a   Uijen, Gerard J H ^a   Reiber, Johan H C ^b   Bruschke, Albert V G ^b   Stalenhoef, Anton F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiography; apheresis; atherosclerosis; coronary disease; lipids; lipoproteins

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; APHERESIS; ARTICLE; BICYCLE ERGOMETRY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG SCREENING; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; ST SEGMENT DEPRESSION;

EID: 0029882936     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.10.1826     Document Type: Article

References (63)

1. Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chron Dis. 1978;1:201-306.
2. Stamler J, Wentworth D, Neaton JN, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA. 1986;256:2823-2828.
3. Vos JA, de Feyter PJ, Simoons ML, Tijssen JGP, Deckers JW. Retardation and arrest of progression or regression of coronary artery disease: a review. Prog Cardiovasc Dis. 1993;35:435-454.
4. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
5. Brown G, Albers JJ, Fisher LD, Sheafer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
6. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990; 264:3007-3012.
7. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.
8. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis H, Deboer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, and the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
9. Haskell WL, Alderman EL, Fair JM, Maron JD, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM, Farquhar JW. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89: 975-990.
10. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J, and the CCAIT Study Group. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
11. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344: 633-638. [Erratum, Lancet. 1994;344:762.]
12. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappart FM, Lie KI, on behalf of the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
13. Blankenhorn DH, Hodis HN. George Lyman Duff Memorial Lecture: Arterial imaging and atherosclerosis reversal. Arterioscler Thromb. 1994;2:177-192.
14. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87: 1781-1791.
15. Superko HR, Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation. 1994;90:1056-1069.
16. Scandinavian Simvastatin Survival Study Group: randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
17. Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low density lipoproteins by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis. 1985;5:613-622.
18. Mabuchi H, Michishita I, Takeda M, Fujita H. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis. 1987;68:19-25.
19. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Br Med J. 1985;291:1671-1673.
20. Koga N, Iwata Y. Pathological and angiographic regression of coronary atherosclerosis by LDL-apheresis in a patient with familial hypercholesterolemia. Atherosclerosis. 1991;90:9-21.
21. Yamamoto A. Regression of atherosclerosis in humans by lowering serum cholesterol. Atherosclerosis. 1991;89:1-10.
22. Gordon BR, Kelsey SF, Bilheimer DW, Brown DC, Dau PC, Gotto AM, Illingworth DR, Jones PH, Leitman SF, Prihoda J, Stein EA, Stern TN, Zavoral JH, Zwiener RJ. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose absorption system. Am J Cardiol. 1992;70:1010-1016.
23. Brown BG, Bolsen EL, Dodge HT. Quantitative computer techniques for analyzing coronary angiograms. Prog Cardiovasc Dis. 1986;28:403-418.
24. Reiber JHC, Serruys PW, Kooijman CJ, Wijns W, Slager CJ, Gerbrands JJ, Schuurbiers JCH, den Boer A, Hugenholtz PG. Assessment of short-, medium-, and long-term variation in arterial dimensions from computer assisted quantitation of coronary cine-angiograms. Circulation. 1985;71:280-288.
25. de Feyter PJ, Serruys PW, Davies MJ, Richardson P, Lubsen J, Oliver MF. Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis: value, limitations, and implications for clinical trials. Circulation. 1991;84: 412-423.
26. Waters D, Lespérance K, Craven TE, Hudon G, Gillam L. Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis: implications for clinical trials. Circulation. 1993;87(suppl II): II-38-II-47.
27. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med. 1995;332:512-521.
28. Stalenhoef AFH, Mol MJTM, Stuyt PMJ. Efficacy and tolerability of simvastatin (MK-733). Am J Med. 1989;4A:39S-43S.
29. Walker JF. Simvastatin: the clinical profile. Am J Med. 1989;4A: 44S-46S.
30. Mabuchi H, Fujita H, Michishita I, Takeda M, Kajinami K, Koizumi J, Takeda R, Takegoshi T, Wakasugi T, Ueda K. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis. Atherosclerosis. 1988;72:183-188.
31. Pfohl M, Naoumova RP, Klass C, Knisei W, Jakober B, Risler T, Thompson GR. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res. 1994;35:1946-1955.
32. Demacker PNM, Hijmans AG, Vos-Jansen HE, van 't Laar A, Jansen AP. A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin Chem. 1980;26:1775-1779.
33. Lopes-Virella MF, Virella G, Evans G, Malenkos SB, Colwell JA. Immunonephelometric assay of human apolipoprotein AI. Clin Chem. 1980;26:1205-1208.
34. Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PWC. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709-715.
35. Mol MJTM, Stalenhoef AFH. Homozygous familial hypercholesterolemia: metabolic studies and treatment with LDL apheresis. Neth J Med. 1990;36:279-287.
36. Apstein CS, Zilversmith DB, Lees RS, George PK. Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia. Atherosclerosis. 1978;31: 105-115.
37. Thompson GR. Plasma exchange for hypercholesterolemia. Lancet. 1981;1:1246-1248.
38. Thompson GR, Maher WMG, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, de Feyter P, Henderson A. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995; 345:811-816.
39. Kroon AA, van 't Hof MA, Stalenhoef AFH. Assessment of time-averaged levels in treatment of hypercholesterolemia by LDL-apheresis (LA). Neth J Med. 1992;40:A50-A51.
40. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LSC, McGoon DC, Murphy ML, Roe BB. A reporting system on patients evaluated for coronary artery disease: report of the ad hoc committee for grading of coronary artery disease, council on cardiovascular surgery, American Heart Association. Circulation. 1975;51:6-34.
41. Reiber JHC, von Land CD, Koning G, van der Zwet PMJ, van Houdt RCM, Schalij MJ, Lespérance J. Comparison of accuracy and precision of quantitative coronary arterial analysis between cinefilm and digital systems. In: Reiber JHC, Serruys PW, eds. Progress in Quantitative Coronary Arteriography. Amsterdam, the Netherlands: Kluwer Academic Publishers; 1994:67-85.
42. Reiber JHC, van der Zwet PMJ, von Land CD, Koning G, van Meurs B, Buis B, van Voorthuisen AE. Quantitative coronary arteriography: equipment and technical requirements. In: Reiber JHC, Serruys PW, eds. Advances in Quantitative Coronary Arteriography. Amsterdam, the Netherlands: Kluwer Academic Publishers; 1992: 75-111.
43. Kroon AA, Mol MJTM, Stalenhoef AFH. ACE inhibitors and LDL-apheresis with dextran sulphate adsorption. Lancet. 1992; 340:1476. Letter.
44. Agishi T. Anion-blood contact reaction (ABC reaction) in patients treated by LDL apheresis with dextran sulfate-cellulose columns while receiving ACE inhibitors. JAMA. 1994;271:195. Letter.
45. Bruschke AVG, Wijers TS, Kolster W, Landmann J. The anatomic evolution of coronary artery disease demonstrated by coronary angiography in 256 nonoperated patients. Circulation. 1981;63: 527-536.
46. Lichtlen PR, Nikutta P, Jost S, Deckers J, Wiese B, Rafflenbeul W, and the INTACT Study Group. Anatomical progression of coronary artery disease in humans as seen by prospective repeated quantitated coronary angiography. Circulation. 1992;86:828-838.
47. Gordon BR, Daal SD. Advances in LDL-apheresis for the treatment of severe hypercholesterolemia. Curr Opin Lipidol. 1994; 5:69-73.
48. Tatami R, Inoue N, Itoh H, Kishino B, Koga K, Nakashima Y, Nishide T, Okamura K, Saito Y, Teramoto T, Yasugi T, Yamamoto A, Goto Y, for the LARS Investigators. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis. 1992;95:1-13.
49. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Dinsenbacher A, Eisenhauer T, Grützmacher P, Keller C, Kettner U, Kleophas W, Köster W, Olbricht CJ, Richter WO, Seidel D, and the HELP-Study Group. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease, II: final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest. 1994;24:724-732.
50. Borberg H, Oette K. Experience with and conclusions from three different trials on low density lipoprotein apheresis. In: Agishi T, Kawamura A, Mineshima M, eds. Therapeutic Plasmapheresis (XII). Utrecht, the Netherlands: VSP; 1993:13-20.
51. Tait GW, Packard CJ, Sheperd J, Hutton I, Lorimer RA. Cholesterol reduction and regression of coronary atherosclerosis: the Coronary Atheroma Regression Study. In: Gordon BR, Gotto AM, eds. The Treatment of Severe Hypercholesterolemia. Princeton, NJ: Exerpta Medica, Inc; 1992:80-89.
52. Watts GF. Familial hypercholesterolaemia regression study and its implications. Lancet. 1995;345:807-808.
53. Jürgens G, Ashy A, Zenker G. Raised serum lipoprotein(a) during treatment with lovastatin. Lancet. 1989;1:911-912.
54. Koizumi J, Koizumi I, Uno Y, Inazu A, Kajinami K, Haraki T, Yagi K, Kamon N, Miyamoto S, Takegoshi T, Mabuchi H, Takeda R, Tani N, Takada S. Reduction of lipoprotein(a) by LDL-apheresis using dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis. 1993;100:65-74.
55. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. JAMA. 1990;264:3013-3017.
56. Fuster V, Badimon JJ, Badimon L. Clinical-pathological correlations of coronary disease progression and regression. Circulation. 1992;86(suppl III):III-1-III-11.
57. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
58. Keller C. LDL-apheresis: results of long-term treatment and vascular outcome. Atherosclerosis. 1991;86:1-8.
59. Knisel W, Di Nicuolo A, Pfohl M, Müller H, Risler T, Eggstein M, Seifried E. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic system. J Intern Med. 1993;234:479-487.
60. Rubba P, Iannuzzi A, Postiglione A, Scarpato N, Montefusco S, Gnasso A, Nappi G, Cortese C, Mancini M. Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia. Circulation. 1990;81: 610-616.
61. Kroon AA, Stalenhoef AFH, Buikema H, Demacker PNM, de Wilde PCM, Leijten PA, van Gilst WH. The effect of cholesterol reduction on endothelial function and progression of atherosclerosis in WHHL rabbits. Atherosclerosis. 1993;103:221-230.
62. Benzuly KH, Padgett RC, Kaul S, Piegors DJ, Armstrong ML, Heistad DD. Functional improvement precedes structural regression of atherosclerosis. Circulation. 1994;89:1810-1818. [Erratum. Circulation. 1994;90:1585.]
63. Bogaty P, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in unstable angina. Circulation. 1994;90:5-11.